Join our daily newsletter At The Bell to receive exclusive market insights
Pro Medicus (ASX:PME) has notched a new all-time high climbing over $280.50/sh on the back of a seven-year deal worth $53M with U.S. player BayCare.
The core product of the deal is Pro Medicus’s Visage 7 – the company calls it “enterprise imaging nirvana” on its website, which is one way to sell a product – which will be embedded into the cloud for BayCare.
BayCare, for those playing at home, is billed as “Central Florida’s largest provider of behavioural health and pediatric services” across 16 hospitals and a wide network of other locations.
BayCare will then be able to take Visage 7 across its multiple locations. The software ultimately allows organisations a scaleable way to store and view scans of patients of varying types (think X-rays, MRI scans, etc).
“When legacy viewers… are collapsed and simplified, value is delivered at all points along the imaging chain,” Pro Medicus writes of its product.
The move ultimately pushes Pro Medicus further into the U.S with a “transaction-based model with potential upside.” The go-live for the BayCare-wide rollout is set for the second half of CY2025.
“BayCare joins our rapidly growing list of integrated delivery network (IDN) clients,” Pro Medicus CEO Dr. Sam Huper said.
“They also join the 70% of all Visage 7 North American clients to opt for a cloud-based solution, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.”
PME last traded at $281.50/sh.
Join the discussion: See what HotCopper users are saying about Pro Medicus and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
